Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M
Source: SeekingAlpha
2025-04-14 08:35:35 ET
More on Can-Fite Biopharma
- Seeking Alpha’s Quant Rating on Can-Fite Biopharma
- Historical earnings data for Can-Fite Biopharma
- Financial information for Can-Fite Biopharma
Read the full article on Seeking Alpha
For further details see:
Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.67M
Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)
NASDAQ: CANF
CANF Trading
-1.17% G/L:
$3.38 Last:
11,149 Volume:
$3.36 Open:
CANF Latest News
May 18, 2026 07:00:00 am
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 13, 2026 07:00:00 am
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
CANF Stock Data
$9,110,276,106
1,960,466,988
N/A
3
N/A
Biotechnology & Life Sciences
Healthcare
IL
Ramat Gan
